CStone gains rights to Blueprint's cancer candidates
Blueprint Medicine Corp. granted CStone Pharmaceuticals Co. Ltd. exclusive rights to develop and sell three of its cancer candidates (as monotherapies or combination regimens) in Mainland China, Hong Kong, Macau, and Taiwan.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com